On January 5, 2018 NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, reported that the company will be hosting an Investor/Analyst Day on Tuesday, January 9th in San Francisco, California (Press release, NantKwest, JAN 5, 2018, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2325070 [SID1234522918]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NantKwest will be sharing with analysts and investors a review of the company’s activities in 2017 and provide a detailed overview for 2018. The record number of 15 INDs authorized in 2017 (aNK, haNK, Cryopreserved haNK and taNK) will be announced, detailing the multiple tumor types to be studied with combination chemo-radiation therapy and activators of adaptive immune system through adenovirus, yeast and super agonist IL-15 platforms. In addition, details will be presented regarding authorization in Europe to treat patients with glioblastoma and authorization by the FDA to initiate high-affinity natural killer (haNK) cell trials in cancer patients with HIV.
First in-human clinical data will be revealed including safety and early signs of clinical activity in patients receiving freshly cultured haNK, cryopreserved haNK and combinations of NK cells (aNK and haNK) with adenovirus, yeast, and super agonist IL-15 platforms. These studies form the basis for multiple Phase II and registration trials anticipated to be initiated in 2018.
At this event, senior management of NantKwest will provide a review of its ongoing R&D program, as well as provide an in-depth clinical trial roadmap for the company’s clinical programs for 2018 and the current status of the GMP manufacturing plants.
A webcast of the event will begin at 7:00 PM PT on Tuesday, January 9, 2018 and is expected to conclude at 9:00 PT. A link to the live webcast can be accessed by visiting the Investors page of the company’s website. In addition, a replay of the event will be posted on the website after the event and will be available for 30 days following the event.